Prednisone vs Cyclosporine for PG: How Is Treatment Chosen?
At a Glance
Prednisolone, a medicine similar to prednisone, and cyclosporine had similar healing results in the STOP-GAP trial, so doctors choose based on diabetes, kidney disease, blood pressure, drug interactions, side-effect risks, and monitoring needs.
New here?
Inciteful Med answers your health questions using peer-reviewed research, with sources you can check. Free to try.
In this answer
3 sections
The short answer is that neither drug is universally “better” at healing pyoderma gangrenosum (PG). Instead, doctors choose between systemic corticosteroids (like prednisone) and cyclosporine based on your personal medical history, existing health conditions, and which side effects are safest for you to manage.
Because both medications suppress your immune system to stop the aggressive inflammation of PG, the decision is a balancing act between the specific risks of the drugs, the severity of your ulcers, and how quickly your disease is progressing [1].
The STOP-GAP Trial: Understanding the Evidence
For years, doctors debated which medication worked faster or better for PG. This was addressed by a major clinical study known as the STOP-GAP trial, which compared oral prednisolone (a medication very similar to prednisone) and cyclosporine (often spelled ciclosporin).
The trial found broadly similar outcomes rather than proving one drug was superior: at the six-month mark, approximately 47% of patients in both groups had completely healed their primary “target ulcer” [2][3]. Furthermore, early healing speeds were similar [2].
While both drugs can begin to reduce active inflammation and pain relatively quickly, complete skin healing takes substantial time. Fewer than 25% of patients in the trial had fully healed ulcers at six weeks [4][3]. Because the success rates are similar, your doctor’s choice comes down to safety, side effect profiles, and your individual health profile rather than one drug having inherently stronger healing power [5][2].
Comparing the Risks and Side Effects
Both drugs are powerful and require careful monitoring. In the STOP-GAP trial, overall adverse reactions (any unwanted side effects) were reported in 66% of the prednisolone group and 68% of the cyclosporine group [2]. Importantly, both drugs suppress the immune system, which means both increase your risk of infections.
Prednisone (Systemic Corticosteroids)
While excellent for rapid inflammation control, the long-term use of corticosteroids requires careful safety checks. Risks include:
- Serious Infections: The STOP-GAP trial found that serious adverse reactions—particularly severe infections—were more common in patients taking prednisolone compared to cyclosporine [2].
- High Blood Sugar: Prednisone can induce diabetes or severely worsen blood sugar control [6][7].
- Bone Loss: Long-term use increases the risk of osteoporosis and bone fractures [8][9].
- Mood and Behavioral Changes: Steroids can cause anxiety, insomnia, mood swings, and behavioral disturbances [8][9].
- Other Risks: Weight gain, high blood pressure, cataracts, and glaucoma [8][9].
Important: Never stop taking prednisone abruptly. Your doctor must provide a taper plan to slowly reduce the dose, as suddenly stopping can cause a life-threatening condition called adrenal insufficiency [10].
Cyclosporine
Cyclosporine is often used as a steroid-sparing agent—a medication used to help patients reduce or avoid the long-term side effects of steroids [10]. However, it has a “narrow therapeutic index,” meaning the difference between an effective dose and a toxic dose is very small [11].
- Kidney Toxicity and High Blood Pressure: Cyclosporine can directly impact kidney function and frequently causes or worsens high blood pressure [10][11].
- Severe Drug Interactions: Cyclosporine interacts dangerously with many common medications (including azole antifungals, macrolide antibiotics, and even grapefruit), which can unexpectedly spike the drug’s levels in your blood [12][13].
- Other Risks: Tremors, gum overgrowth, electrolyte imbalances (like elevated potassium), and increased infection risk [11].
Comparison Summary
| Feature | Prednisone / Prednisolone | Cyclosporine |
|---|---|---|
| Primary Risks | Serious infections, high blood sugar, bone loss, mood changes | Kidney toxicity, high blood pressure, complex drug interactions |
| Key Monitoring | Blood sugar, blood pressure, bone health, eye exams, infection signs | Kidney function (blood tests), blood pressure, drug levels, electrolytes |
| Important Caution | Never stop abruptly. Must be tapered safely under medical supervision. | Must review all medications, supplements, and OTC drugs with pharmacist. |
How Your Care Team Makes the Choice
To make the safest choice, your doctor will look at your whole health picture—often referred to as your comorbidities (other medical conditions you have). This is a highly individualized process [1].
- Your Existing Health Conditions: If you have poorly controlled diabetes, a history of severe steroid-related mood symptoms, or high fracture risk, your doctor may lean away from prednisone [7][6]. Conversely, if you have chronic kidney disease or uncontrolled high blood pressure, cyclosporine may be less suitable [10][14].
- Associated Inflammatory Diseases: If your PG is linked to a condition like ulcerative colitis or Crohn’s disease, your treatment requires coordination between your dermatologist and gastroenterologist. In these cases, a biologic medication (a targeted immune therapy like infliximab) might be considered, as it has evidence for treating both the bowel disease and the skin ulcers [1][15].
- Monitoring Requirements: Both drugs require strict safety monitoring, but cyclosporine often involves very frequent lab visits to check kidney function and drug levels in your blood [11][16]. You and your doctor will discuss local lab access and the logistical requirements of this testing.
- Wound Care and Pathergy: Systemic medication is only one part of PG treatment. PG is notorious for pathergy, meaning that trauma or aggressive wound cleaning can cause the ulcers to worsen. Gentle wound care is essential, and your doctor will monitor for any signs of superimposed infection in the wound itself [1][17].
If you experience fever, rapidly increasing redness, excessive wound drainage, or a sudden worsening of your ulcer, contact your medical team immediately, as these can be signs of infection while your immune system is suppressed.
Common questions in this guide
Is prednisone or cyclosporine more effective for pyoderma gangrenosum?
How do doctors decide which medicine to use for PG?
What are the main risks of prednisone for pyoderma gangrenosum?
What should I know about cyclosporine safety and monitoring?
Can I stop prednisone once my ulcer starts improving?
How quickly do prednisone or cyclosporine heal pyoderma gangrenosum ulcers?
What symptoms should prompt me to contact my care team during treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my personal health history, which of these two medications carries less risk for my specific body?
- 2.If we start with prednisone, what is our plan and timeline for tapering off to avoid long-term side effects?
- 3.What specific blood work and monitoring will I need for my chosen medication, and how often will I need it?
- 4.Could any of my current daily medications, supplements, or over-the-counter drugs interact with cyclosporine?
- 5.Since my ulcer might take months to heal fully, what specific signs (like reduced pain or less inflammation) will tell us the medication is working in the first few weeks?
- 6.How will we ensure my wound care is gentle enough to avoid pathergy (worsening the ulcer through trauma)?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
The safety of treatments used in pyoderma gangrenosum.
Feldman SR, Lacy FA, Huang WW
Expert opinion on drug safety 2018; (17(1)):55-61 doi:10.1080/14740338.2018.1396316.
PMID: 29065721 - 2
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.
Ormerod AD, Thomas KS, Craig FE, et al.
BMJ (Clinical research ed.) 2015; (350()):h2958 doi:10.1136/bmj.h2958.
PMID: 26071094 - 3
Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials.
Partridge ACR, Bai JW, Rosen CF, et al.
The British journal of dermatology 2018; (179(2)):290-295 doi:10.1111/bjd.16485.
PMID: 29478243 - 4
Pyoderma gangrenosum.
Maverakis E, Marzano AV, Le ST, et al.
Nature reviews. Disease primers 2020; (6(1)):81 doi:10.1038/s41572-020-0213-x.
PMID: 33033263 - 5
Pyoderma gangrenosum: Classic and emerging therapies.
Soto Vilches F, Vera-Kellet C
Medicina clinica 2017; (149(6)):256-260 doi:10.1016/j.medcli.2017.04.013.
PMID: 28629662 - 6
Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report.
Anwar S, Holfeld K, Prasad B
Case reports in nephrology and dialysis 2018; (8(3)):239-245 doi:10.1159/000493188.
PMID: 30574505 - 7
Corticosteroid therapy for nephrotic syndrome in children.
Hahn D, Samuel SM, Willis NS, et al.
The Cochrane database of systematic reviews 2024; (8()):CD001533 doi:10.1002/14651858.CD001533.pub7.
PMID: 39171624 - 8
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.
Lancet (London, England) 2017; (389(10083)):2031-2040 doi:10.1016/S0140-6736(17)30070-3.
PMID: 28342637 - 9
A Comprehensive Review of Local Pharmacologic Therapy for Pyoderma Gangrenosum.
Baltazar D, Haag C, Gupta AS, et al.
Wounds : a compendium of clinical research and practice 2019; (31(6)):151-157.
PMID: 31215868 - 10
Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review.
Hrin ML, Bashyam AM, Huang WW, Feldman SR
International journal of dermatology 2021; (60(12)):e486-e492 doi:10.1111/ijd.15539.
PMID: 33739458 - 11
Cyclosporin in dermatology: A practical compendium.
Amber T, Tabassum S
Dermatologic therapy 2020; (33(6)):e13934 doi:10.1111/dth.13934.
PMID: 32602210 - 12
Impact of posaconazole tablets for secondary prophylaxis on drug interactions in haploidentical allogeneic stem cell transplantation: A single-arm, open-label, prospective study.
Wang X, Wang Y, He P
Cell transplantation 2025; (34()):9636897251378570 doi:10.1177/09636897251378570.
PMID: 41159371 - 13
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant.
de Truchis C, Bouazza N, Foissac F, et al.
British journal of clinical pharmacology 2023; (89(5)):1532-1540 doi:10.1111/bcp.15610.
PMID: 36510685 - 14
Combination Doxycycline and Topical Corticosteroids in the Treatment of Ulcerative Pyoderma Gangrenosum: A Case Report.
Manalo-Legas DMLM, Calayag EMTD, Chen ELA
Acta medica Philippina 2024; (58(17)):79-82 doi:10.47895/amp.v58i17.7462.
PMID: 39431260 - 15
Treatment options for pyoderma gangrenosum.
Quist SR, Kraas L
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017; (15(1)):34-40 doi:10.1111/ddg.13173.
PMID: 28140549 - 16
Relapse of Steroid-Dependent Nephrotic Syndrome Despite Long-Term Ciclosporin Therapy in an 11-Year-Old Child: A Case Report and Review on the Management of Nephrotic Syndrome in Children.
Zaihan AF, Jamil N, Kow CS
Case reports in nephrology 2026; (2026()):1396986 doi:10.1155/crin/1396986.
PMID: 42609695 - 17
Treatment of Pyoderma Gangrenosum.
Tan MG, Tolkachjov SN
Dermatologic clinics 2024; (42(2)):183-192 doi:10.1016/j.det.2023.12.002.
PMID: 38423680
This page is for informational purposes only and does not constitute medical advice. A dermatologist and your other clinicians should choose and monitor prednisone or cyclosporine based on your health history, medicines, and ulcer severity.
Get notified when new evidence is published on Pyoderma gangrenosum.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.